Amgen Inc. (AMGN)
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
Amgen ( AMGN ) is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in.
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
Amgen delivers Q4 earnings and revenue beat, driven by strong drug volumes, as attention turns to its late-stage MariTide obesity studies.
Why Amgen Stock Is Paying Off Big For Long-Term Investors
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in the global market.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
Amgen delivered a strong Q4 2025, exceeding revenue and EPS expectations and guiding for 2026 growth despite major loss of exclusivity headwinds. Key branded products Repatha, Uplizna, Evenity, Imdelltra, and Tezspire are expected to offset losses from Prolia, Xgeva, and Ravicti. Regulatory uncertainty around Tavneos adds risks, and pipeline attrition (rocatinlimab, bemarituzumab) is not ideal, but positive Repatha data and MariTide progress support the long-term thesis.
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Amgen (AMGN) Q4 Earnings
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates
Amgen (AMGN) came out with quarterly earnings of $5.29 per share, beating the Zacks Consensus Estimate of $4.76 per share. This compares to earnings of $5.31 per share a year ago.
Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost
The biotechnology company reported a quarterly profit of $1.33 billion, attributing its boost in earnings to higher revenue and lower net unrealized losses on equity investments.
Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% increase in drug sales and a lower tax rate.
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
